Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. MYCN (V-myc myelocytomatosis viral-related oncogene, neuroblastoma derived [avian]) is amplified in 20% of neuroblastomas, and these tumors carry a poor prognosis. However, tumors without MYCN amplification also may have a poor outcome. Here, we identified downstream targets of MYCN by shRNA-mediated silencing MYCN in neuroblastoma cells. From these targets, 157 genes showed an expression profile correlating with MYCN mRNA levels in NB88, a series of 88 neuroblastoma tumors, and therefore represent in vivo relevant MYCN pathway genes. This 157-gene signature identified very poor prognosis tumors in NB88 and independent neuroblastoma cohorts and was more powerful than MYCN amplification or MYCN expression alone. Remarkably, this signature also identified poor outcome of a group of tumors without MYCN amplification. Most of these tumors have low MYCN mRNA levels but high nuclear MYCN protein levels, suggesting stabilization of MYCN at the protein level. One tumor has an MYC amplification and high MYC expression. Chip-on-chip analyses showed that most genes in this signature are directly regulated by MYCN. MYCN induces genes functioning in cell cycle and DNA repair while repressing neuronal differentiation genes. The functional MYCN-157 signature recognizes classical neuroblastoma with MYCN amplification, as well as a newly identified group marked by MYCN protein stabilization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroblastoma: Biology, Prognosis, and Treatment
Park, J. R., Eggert, A., & Caron, H. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.011 · Cited by 620 · cited 5×
“The prognosis is highly variable and is associated with parameters such as age at diagnosis, dissemination at time of diagnosis, tumor stage, and grade of differentiation of the primary tumor (1).”
BackgroundMethodInfluentialStabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
Otto, T., Horn, S., Brockmann, M., Eilers, U., Schüttrumpf, L., Popov, N., Kenney, A. M., Schulte, J. H., Beijersbergen, R., Christiansen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.005 · Cited by 573 · cited 3×
“Also, FBXW7 and AURKA have been shown to regulate MYCN protein stability (10).”
BackgroundInfluentialCuzick, J. M., Šestak, I., Pinder, S. E., Ellis, I. O., Forsyth, S., Bundred, N. J., Forbes, J., Bishop, H., Fentiman, I. S., & George, W. D. (2013) · Cited by 423
An alternative pathway for gene regulation by Myc
Peukert, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.18.5672 · Cited by 364 · cited 1×
“Several mechanisms have been described, including interference with transcription factors MIZ1 and Sp1 (12, 13) and induction of microRNA expression (14, 15).”
BackgroundGene expression analyses reveal molecular relationships among 20 regions of the human CNS
Roth, R. B., Hevezi, P., Lee, J., Willhite, D., Lechner, S. M., Foster, A. C., & Zlotnik, A. (2006) · Neurogenetics · doi:10.1007/s10048-006-0032-6 · Cited by 342 · cited 1×
“Normal tissues [green (30)] are divided in the 10 groups indicated below.”
BackgroundLutz, W., Stöhr, M., Schürmann, J., Wenzel, A., Löhr, A., & Schwab, M. (1996) · PubMed · Cited by 312
Oberthuer, A., Berthold, F., Warnat, P., Hero, B., Kahlert, Y., Spitz, R., Ernestus, K., König, R., Haas, S., Eils, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1879 · Cited by 291 · cited 2×
“Clustering of tumors based on this signature was highly predictive for prognosis, even in a large neuroblastoma series analyzed on a different platform (11) (Fig.”
BackgroundResultMYCN regulates oncogenic MicroRNAs in neuroblastoma
Schulte, J. H., Horn, S., Otto, T., Samans, B., Heukamp, L. C., Eilers, U., Krause, M., Astrahantseff, K., Klein‐Hitpass, L., Buettner, R., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23153 · Cited by 267 · cited 1×
“Several mechanisms have been described, including interference with transcription factors MIZ1 and Sp1 (12, 13) and induction of microRNA expression (14, 15).”
BackgroundWestermann, F., Muth, D., Benner, A., Bauer, T., Henrich, K.-O., Oberthuer, A., Brors, B., Beissbarth, T., Vandesompele, J., Pattyn, F., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-10-r150 · Cited by 264 · cited 1×
“Usually, MYCN gene regulation and binding to promoter regions are performed in the SHEP-21N cell line with ectopic expression ofMYCN (2, 16, 23).”
BackgroundKenney, A. M., Widlund, H. R., & Rowitch, D. H. (2004) · Development · doi:10.1242/dev.00891 · Cited by 214 · cited 4×
“The MYCN protein was found to be destabilized by phosphorylation by GSK3β (7, 8).”
BackgroundInfluentialYu, Z., Chen, T., Hébert, J., Li, E., & Richard, S. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00042-09 · Cited by 208 · cited 1×
“PRMT1 recently was shown to direct the recruitment of RAD51 to DNA damage sites (26).”
BackgroundChesler, L., Schlieve, C., Goldenberg, D. D., Kenney, A., Kim, G., McMillan, A., Matthay, K. K., Rowitch, D., & Weiss, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2769 · Cited by 202 · cited 5×
“Accordingly, activation of the PI3K/AKT pathway in neuroblastoma cell lines resulted in stabilization of MYCN protein (7, 8).”
BackgroundInfluentialVermeulen, J., De Preter, K., Naranjo, A., Vercruysse, L., Van Roy, N., Hellemans, J., Swerts, K., Bravo, S., Scaruffi, P., Tonini, G. P., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70154-8 · Cited by 192
Fredlund, E., Ringnér, M., Maris, J. M., & Påhlman, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804455105 · Cited by 169 · cited 2×
“A biological profile derived from the literature that predicts outcome has been described before (22).”
BackgroundMethodInactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
Molenaar, J. J., Ebus, M. E., Geerts, D., Koster, J., Lamers, F., Valentijn, L. J., Westerhout, E. M., Versteeg, R., & Caron, H. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901418106 · Cited by 167 · cited 2×
“Interestingly, we recently showed that CDK2 is synthetically lethal to MYCN, as silencing of CDK2 was lethal only in neuroblastoma cells with MYCN overexpression (28).”
BackgroundMethodSelf-citationOhira, M., Oba, S., Nakamura, Y., Isogai, E., Kaneko, S., Nakagawa, A., Hirata, T., Kubo, H., Goto, T., Yamada, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.019 · Cited by 155
Lovén, J., Zinin, N., Wahlström, T., Müller, I., Brodin, P., Fredlund, E., Ribacke, U., Pivarcsi, A., Påhlman, S., & Henriksson, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913517107 · Cited by 136 · cited 1×
“Several mechanisms have been described, including interference with transcription factors MIZ1 and Sp1 (12, 13) and induction of microRNA expression (14, 15).”
BackgroundCaron, H. N., Sluis, P. V., van Hoeve, M., de Kraker, J., Bras, J., Slater, R. M., Mannens, M. M. A. M., Voûte, P. A., Westerveld, A., & Versteeg, R. (1993) · Nature Genetics · doi:10.1038/ng0693-187 · Cited by 134
Self-citationMYCN oncoprotein targets and their therapeutic potential
Bell, E., Chen, L., Liu, T., Marshall, G. M., Lunec, J., & Tweddle, D. A. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.01.015 · Cited by 126 · cited 2×
“High expression of MYCN is associated with fast proliferation and induction of cell cycle genes [(2–5) and reviewed by Bell (5)].”
BackgroundClausen, D. M., Guo, J., Parise, R. A., Beumer, J. H., Egorin, M. J., Lazo, J. S., Prochownik, E. V., & Eiseman, J. L. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170555 · Cited by 117 · cited 1×
“As pharmacological targeting of MYC and MYCN thus far has been unsuccessful (27), targeting of MYC(N) downstream pathway genes might provide an alternative option.”
BackgroundSchramm, A. R., Schulte, J. H., Klein‐Hitpaß, L., Havers, W., Sieverts, H., Berwanger, B., Christiansen, H., Warnat, P., Brors, B., Eils, J., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208936 · Cited by 117
Henriksen, J. R., Haug, B. H., Buechner, J., Tømte, E., Løkke, C., Flægstad, T., & Einvik, C. (2011) · BMC Developmental Biology · doi:10.1186/1471-213x-11-1 · Cited by 101 · cited 1×
“Recent silencing of MYCN with siRNA (25) or inducible shRNA (4) in MYCN-amplified neuroblastoma cell lines shows that MYCN regulates the cycle via induction of known cell cycle genes.”
BackgroundIraci, N., Diolaiti, D., Papa, A., Porro, A., Valli, E., Gherardi, S., Herold, S., Eilers, M., Bernardoni, R., Valle, G. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2627 · Cited by 100 · cited 1×
“Several mechanisms have been described, including interference with transcription factors MIZ1 and Sp1 (12, 13) and induction of microRNA expression (14, 15).”
BackgroundŁastowska, M., Viprey, V. F., Santibanez‐Koref, M., Wappler, I., Peters, H., Cullinane, C., Roberts, P., Hall, A. G., Tweddle, D. A., Pearson, A. D. J., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210552 · Cited by 97
MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan, H. S. L., Gallie, B. L., DeBoer, G., Haddad, G., Ikegaki, N., Dimitroulakos, J., Yeger, H., & Ling, V. W. T. (1997) · PubMed · Cited by 97
Segerström, L., Baryawno, N., Sveinbjørnsson, B., Wickström, M., Elfman, L. H. M., Kogner, P., & Johnsen, J. I. (2011) · International Journal of Cancer · doi:10.1002/ijc.26268 · Cited by 73 · cited 2×
“Inactivation of the pathway using a PI3K inhibitor resulted in reduced levels of MYCN (9).”
BackgroundDirect regulation of the minichromosome maintenance complex by MYCN in neuroblastoma
Koppen, A., Ait‐Aissa, R., Köster, J., Sluis, P. V., Øra, I., Caron, H. N., Volckmann, R., Versteeg, R., & Valentijn, L. J. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.024 · Cited by 54 · cited 2×
“This confirms previous reports; genes such asMCM3 andMCM5 were directly bound and induced byMYCN (16).”
BackgroundResultSelf-citationUse of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma
Woo, C., Tan, F., Cassano, H., Lee, J. H., Lee, K. C., & Thiele, C. J. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21195 · Cited by 51 · cited 1×
“Recent silencing of MYCN with siRNA (25) or inducible shRNA (4) in MYCN-amplified neuroblastoma cell lines shows that MYCN regulates the cycle via induction of known cell cycle genes.”
BackgroundFix, A., Lucchesi, C., Ribeiro, A., Lequin, D., Pierron, G., Schleiermacher, G., Delattre, O., & Janoueix‐Lerosey, I. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20583 · Cited by 50 · cited 1×
“Four independent neuroblastoma series [red: NB30 (31), NB51, NB64 (32), and NB88] are named after the sample number in the group.”
BackgroundWarnat, P., Oberthuer, A., Fischer, M., Westermann, F., Eils, R., & Brors, B. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-89 · Cited by 32
Oberthuer, A., Warnat, P., Kahlert, Y., Westermann, F., Spitz, R., Brors, B., Hero, B., Eils, R., Schwab, M., Berthold, F., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.016 · Cited by 20
Cited by
Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Pinto, N. R., Applebaum, M. A., Volchenboum, S. L., Matthay, K. K., London, W. B., Ambros, P. F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4648 · Cited by 911
Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles
Walz, S., Lorenzin, F., Morton, J., Wiese, K. E., von Eyss, B., Herold, S., Rycak, L., Dumay-Odelot, H., Karim, S., Bartkuhn, M., et al. (2014) · Nature · doi:10.1038/nature13473 · Cited by 502
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma
Bonilla, X., Parmentier, L., King, B., Bezrukov, F., Kaya, G., Zoete, V., Seplyarskiy, V. B., Sharpe, H. J., McKee, T., Letourneau, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3525 · Cited by 490
Neuroblastoma: Molecular Pathogenesis and Therapy
Louis, C. U., & Shohet, J. M. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-011514-023121 · Cited by 354
Metadata
- Authors
- Valentijn, L. J., Koster, J., Haneveld, F., Aissa, R. A., van Sluis, P., Broekmans, M. E. C., Molenaar, J. J., van Nes, J., & Versteeg, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-10-22
- Volume
- 109
- Issue
- 47
- Pages
- 19190-19195
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2104096565
- Cited by
- 228
- References
- 31
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.